



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

24 February 2020
EMADOC-628903358-1672

Public summary of opinion on orphan designation

2-(Isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one for the treatment of tenosynovial giant cell tumour, localised and diffuse type

On 16 December 2019, orphan designation EU/3/19/2227 was granted by the European Commission to Pharma Gateway AB, Sweden, for 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one (also known as DCC-3014) for the treatment of tenosynovial giant cell tumour, localised and diffuse type.

What is tenosynovial giant cell tumour, localised and diffuse type?

Tenosynovial giant cell tumour is a condition where the tissue surrounding the joints and tendons, called the synovial lining or synovium, expands abnormally forming outgrowths of the joint. It is known as 'localised' if only one site of the joint is affected, or 'diffuse' when several sites are affected. It usually affects a single joint in the hand, knee or hip of young and middle-aged adults and is characterised by pain, swelling and stiffness of the joint.

Tenosynovial giant cell tumour is a long-term debilitating disease because it leads to loss of joint function and joint damage.

What is the estimated number of patients affected by the condition?

At the time of designation, tenosynovial giant cell tumour affected approximately 3 in 10,000 people in the European Union (EU). This was equivalent to a total of around 93,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 518,400,000 (Eurostat 2019).



What treatments are available?

At the time of designation, no satisfactory methods were authorised in the EU for the treatment of tenosynovial giant cell tumour and treatment consisted of surgery and medicines to reduce inflammation.

How is this medicine expected to work?

Tenosynovial giant cell tumours release an excessive amount of a protein called CSF1. This protein attracts more cells and makes them multiply, so making the tumour grow larger. The medicine stops the receptors (targets) for CSF1 on the cells working properly. By reducing the effect of CSF1, the medicine is expected to reduce growth of the tumour and so reduce symptoms of the disease.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with tenosynovial giant cell tumour were ongoing.

At the time of submission, the medicine was not authorised anywhere in the EU for the treatment of tenosynovial giant cell tumour, localised and diffuse type, or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000, the COMP adopted a positive opinion on 7 November 2019, recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

For more information

Sponsor's contact details:

Contact details of the current sponsor for this orphan designation can be found on [EMA website](#).

For contact details of patients' organisations whose activities are targeted at rare diseases see:

- [Orphanet](#), a database containing information on rare diseases, which includes a directory of patients' organisations registered in Europe;

- [European Organisation for Rare Diseases \(EURORDIS\)](#), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

Translations of the active ingredient and indication in all official EU languages¹, Norwegian and Icelandic

Language	Active ingredient	Indication
English	2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one	Treatment of tenosynovial giant cell tumour, localised and diffuse type
Bulgarian	2-(изопропиламино)-3-метил-5-(6-метил-5-((2-(1-метил-1H-пиразол-4-yl)пиридин-4-ил)окси)пиридин-2-ил)пиримидин-4(3H)-он	Лечение на теносиновиален гигантоклетъчен тумор, локализиран и дифузен тип
Croatian	2-(izopropilamino)-3-metil-5-(6-metil-5-((2-(1-metil-1H-pirazol-4-il)piridin-4-il)oksi)piridin-2-il)pirimidin-4(3H)-on	Liječenje gigantocelularnog tenosinovijalnog tumora, lokalizirani i difuzni tip
Czech	2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-on	Léčba tenosynoviálního obrovskobuněčného tumoru, lokalizovaného a difúzního typu
Danish	2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-on	Behandling af tenosynovial kæmpecelletumor, lokaliseret og diffus type
Dutch	2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridine-4-yl)oxy)pyridine-2-yl)pyrimidine-4(3H)-on	Behandeling van tenosynoviale reusceltumoren, gelokaliseerd en diffuus type
Estonian	2-(isopropüülamino)-3-metüül-5-(6-metüül-5-((2-(1-metüül-1H-pürasool-4-üül)püridiin-4-üül)oksü)püridiin-2-üül)pürimidiin-4(3H)-oon	Lokaliseerunudja difuusse tenosünoviaalse hiidrakulise kasvaja ravi
Finnish	2-(isopropyyliamino)-3-metyyli-5-(6-metyyli-5-((2-(1-metyyli-1H-pyratsol-4-yyli)pyridiini-4-yyli)oksi)pyridiini-2-yyli)pyrimidiini-4(3H)-oni	Jännetupen jättisolukasvaimen hoito paikallinen ja diffuusi tautimuoto
French	2-(Isopropylamino)-3-méthyl-5-(6-méthyl-5-((2-(1-méthyl-1H-pyrazole-4-yl)pyridine-4-yl)oxy)pyridine-2-yl)pyrimidin-4(3H)-one	Traitement des tumeurs ténosynoviales à cellules géantes, localisées ou diffuses
German	2-(Isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-on	Behandlung des tenosynovialen Riesenzelltumors vom lokalisierten und diffusen Typ
Greek	2-(Ισοπροπουλαμινό)-3-μεθυλο-5-(6-μεθυλο-5-((2-(1-μεθυλο-1H-πυραζολο-4-υλο)πυριδινό-4-υλο)οξυ)πυριδινό-2-υλο)πυριμιδίν-4(3H)-όνη	Θεραπεία του τενοντο-αρθρικού γιγαντοκυτταρικού όγκου, εντοπισμένου κατι διαχύτου τύπου

¹ At the time of designation

Language	Active ingredient	Indication
Hungarian	2-(izopropilamino)-3-metil-5-(6-metil-5-((2-(1-metil-1H-pirazol-4-il)piridin-4-il)oksi)piridin-2-il)pirimidin-4(3H)-on	Lokalizált és diffúz típusú tenosynovialis óriássejtes tumor kezelésére
Italian	2-(isopropilamino)-3-metil-5-(6-metil-5-((2-(1-metil-1H-pirazolo-4-il)piridin-4-il)ossi)piridin-2-il)pirimidin-4(3H)-one	Trattamento della sinovite pigmentata villonodulare e tumore tenosinoviale a cellule giganti localizzata e diffusa
Latvian	2-(izopropilamino)-3-metil-5-(6-metil-5-((2-(1-metil-1H-pirazol-4-il)piridīn-4-il)oksi)piridīn-2-il)pirimidīn-4(3H)-ons	Vietēja un difūza tipa tenosinoviālo gigantisko šūnu audzēja ārstēšana
Lithuanian	2-(izopropilamino)-3-metil-5-(6-metil-5-((2-(1-metil-1H-pirazol-4-il)piridin-4-il)oksi)piridin-2-il)pirimidin-4(3H)-onas	Tenosinovialinių stambiųjų ląstelių naviko gydymas, lokalus ir išplitęs tipas
Maltese	2-(isopropilammīno)-3-metil-5-(6-metil-5-((2-(1-metil-1H-pirazol-4-yl)piridin-4-il)ossi)piridin-2-il)pirimidin-4(3H)-one	Kura ta' tumor tenosinovjali b'ċelluli ġganteski, ta' tip lokalizzat u diffuż
Polish	2-(izopropylamino)-3-metylo-5-(6-metylo-5-((2-(1-metylo-1H-pirazolo-4-yl)piridyno-4-yl)oksy)piridino-2-yl)pirimidyno-4(3H)-on	Leczenie guza olbrzymiokomórkowego pochewki ścięgnowej, typu zlokalizowanego i rozsianego
Portuguese	2-(isopropilamino)-3-metil-5-(6-metil-5-((2-(1-metil-1H-pirazol-4-il)piridin-4-il)oxi)piridin-2-il)pirimidin-4(3H)-ona	Tratamento do tumor tenosinovial de células gigantes, de tipo localizado e difuso
Romanian	2-(izopropilamino)-3-metil-5-(6-metil-5-((2-(1-metil-1H-pirazol-4-il)piridin-4-il)oxi)piridin-2-il)pirimidin-4(3H)-onă	Tratamentul tumorilor tenosinoviale cu celule gigante, tipurile localizat și difuz
Slovak	2-(izopropylamino)-3-metyl-5-(6-metyl-5-((2-(1-metyl-1H-pyrazol-4-yl)pyridín-4-yl)oxy)pyridín-2-yl)pyrimidín-4(3H)-ón	Liečba tendosynoviálneho obrovskobunkového nádoru, lokalizovaného a difúzneho typu
Slovenian	2-(izopropilamino)-3-metil-5-(6-metil-5-((2-(1-metil-1H-pirazol-4-il)piridin-4-il)oksi)piridin-2-il)pirimidin-4(3H)-on	Zdravljenje tenovialnega gigantocelularnega tumorja, lokaliziran in difuzni tip
Spanish	2-(isopropilamina)-3-metil-5-(6-metil-5-((2-(1-metil-1H-pirazol-4-il)piridina-4-il)oxi)piridina-2-il)pirimidina-4(3H)-ona	Tratamiento de tumores tenosinoviales de células gigantes, localizados o difusos.
Swedish	2-(Isopropylamino)-3-metyl-5-(6-metyl-5-((2-(1-metyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-on	Behandling av tenosynovial jättecellstumör, lokaliserad och diffus
Norwegian	2-(isopropylamin)-3-metyl-5-(6-metyl-5-((2-(1-metyl-1H-pyrazol-4-yl)pyridin-4-yl)oksy)pyridin-2-yl)pyrimidin-4(3H)-on	Behandling av tenosynovial kjempecelletumor, lokalisert og diffus type
Icelandic	2-(Ísóprópýlaminó)-3-metýl-5-(6-metýl-5-((2-(1-metýl-1H-pýrasól-4-yl)pýridín-4-ýl)oxý)pýridín-2-yl)pýrimídín-4(3H)-on	Meðferð við risafrumuæxli í sinaslíðri og hála af staðbundinn gerð og úbreitt